Greenfield Seitz Capital Management, LLC Gilead Sciences, Inc. Transaction History

Greenfield Seitz Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Nov 24, 2025	SELL	$89.14 - $117.41 $616,313 - $811,772	-6,914 Closed	0 $0
Q4 2024 Nov 24, 2025	BUY	$83.95 - $97.9 $1,679 - $1,958	20 Added 0.29%	6,914 $639 Million
Q3 2024 Nov 24, 2025	SELL	$66.59 - $83.99 $84,835 - $107,003	-1,274 Reduced 15.6%	6,894 $578 Million
Q2 2024 Nov 24, 2025	SELL	$63.15 - $72.88 $116,764 - $134,755	-1,849 Reduced 18.46%	8,168 $560 Million
Q1 2024 Nov 24, 2025	SELL	$71.58 - $87.29 $334,636 - $408,080	-4,675 Reduced 31.82%	10,017 $734 Million

Q4 2023 Nov 24, 2025	BUY	$73.27 - $83.09 $1.08 Million - $1.22 Million	14,692 New	14,692 $1.19 Billion

2,368

1.01B

8.63M

7.39M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $156B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Greenfield Seitz Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Greenfield Seitz Capital Management, LLC with notifications on news.